Trial Profile
NYK 1001 in patients with atrial fibrillation: a proof-of-concept study
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2011
Price :
$35
*
At a glance
- Drugs NYK 1001 (Primary)
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors Nyken
- 11 Jan 2011 New trial record